Healthcare News Monitor

Sun Pharma launches Favipiravir in India at Rs 35 per tablet

India TV

Drug major Sun Pharmaceutical Industries on Tuesday said it has launched antiviral drug Favipiravir under the brand name FluGuard for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India. The stocks of FluGuard will be available in the market from this week, Sun Pharma said in a regulatory filing. ,Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease, it added. ,"We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. ,This is in line with our continuous efforts to support Indias pandemic response," Sun Pharma India Business CEO Kirti Ganorkar said.

Jubilant Life Sciences launches JUBI-R for COVID-19 treatment

ExpressPharma

Jubilant Life Sciences’ subsidiary, Jubilant Generics has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection). ,The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. ,A company statement informed, “Jubilant’s 24-hour helpline will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes. In order to increase the accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at the distribution of the drug.”

In the pharma industry, technology has become a mandate for some compliances

Express Pharma

The importance of information technology and its potential to enhance the life sciences industry’s performance has been accentuated by the COVID-19 crisis. Therefore, the whole value chain in the pharma sector is expected to see far-reaching changes. Bino George, Director, Solution Consulting, Infor India, explains how the Indian pharma sector can gain a competitive edge by becoming more compliant, efficient and proactive with technology-adoption and how his company can partner the pharma sector in this transformation

Another Hyderabad hospital barred from treating Covid patients

The Indian Express

Another private hospital in Hyderabad is under fire following several complaints regarding overcharging coronavirus patients. On Tuesday evening, the Telangana government issued orders prohibiting Virinchi Hospital from offering treatment to COVID-19 patients — nearly 24 hours after it took a similar action against Deccan Hospital over ‘surplus billing’. ,According to the latest orders, both hospitals are barred from admitting or treating any confirmed or suspected case of COVID-19. ,The office of the director of Public Health and Family Welfare has directed the management of Virinchi hospital to ensure treatment to patients who are currently admitted there and charge them in accordance with government’s fixed price-cap. It has also warned the hospital against cancellation of its registration if it failed to comply with government norms.